Maryam Barkhordarian
@MaryamBMD
Followers
896
Following
1K
Statuses
2K
Fellow @cardionerds, Internal Medicine resident @HMHPMCIM , Aspiring Cardiologist
New Jersey, USA
Joined January 2021
We @CardioNerds will be at #AHA24 📡 Follow us for 📺 live 📻 updates from #AHA24 🫀 @AmitGoyalMD @Dr_DanMD @Gurleen_Kaur96 @sukritibanthiya @catweneboah @NaimaMaqsood9 @Shikha_Cardio @DanAmponsahMD @AtefehGho @Ronaldo_CFF
📣 FOMO on #AHA24? Catch all the🫀🗞️highlights from the CardioNerds Conference Scholars by following @CardioNerds & #AHA24👩⚕️👨⚕️ @AmitGoyalMD @Dr_DanMD @NaimaMaqsood9 @Gurleen_Kaur96 @Ronaldo_CFF @catweneboah @AtefehGho @MaryamBMD @Shikha_Cardio @DanAmponsahMD
0
6
31
RT @ClaireCambron: Calling all @CardioNerds and #ACHD enthusiasts 🗣️ Join us in celebrating #HeartMonth by submitting your personal artwor…
0
25
0
RT @RawanAAmir: An absolute legend in the making 🌟 So proud of @sukritibanthiya for bagging the Carole Warnes Travel Scholarship🫀🤩 Watch o…
0
2
0
RT @n_marreromed: 20/20: To learn more, check out the CardioNerds Infographic on Lipoprotein(a). And a BIG thanks to my mentors and @Cardi…
0
5
0
RT @n_marreromed: 18/20: I feel comfortable describing the impact of Lp(a) on ASCVD risk stratification and understand the currently and fu…
0
2
0
RT @n_marreromed: 17/20: Today we learned about: 🔺The structure and pathophysiology of Lp(a) 🔺The epidemiology of Lp(a) 🔺The impact of elev…
0
4
0
RT @n_marreromed: 15/20: Olpaseran, a silencing RNA that inhibits LPA mRNA, was found to reduce Lp(a) by >90% in the Phase II OCEAN(a)-DOSE…
0
3
0
RT @n_marreromed: 14/20: Excitement exists around 5 potential future therapies. Pelacarsen, an anti-sense oligonucleotide that inhibits LPA…
0
3
0
RT @n_marreromed: 13/20: In addition to LDL-C reduction, clinicians should prioritize smoking cessation, weight loss, blood pressure manage…
0
3
0
RT @n_marreromed: 12/20: Aggressive ASCVD risk mitigation should emphasize LDL-C reduction using high-intensity statins and non-statin lipi…
0
3
0
RT @n_marreromed: 11/20: Regarding our patient, his elevated Lp(a) would change his risk stratification by the pooled cohort equation from…
0
3
0
RT @n_marreromed: 10/20: ESC & NLA recommend measuring Lp(a) once in a lifetime. AHA/ACC recommend consideration of Lp(a) as a risk enhanci…
0
4
0
RT @n_marreromed: 9/20: Elevated Lp(a), Lp(a) > 105 nmol/L,⬆️baseline ASCVD risk 1.4-fold, with higher concentrations conferring greater ri…
0
4
0
RT @n_marreromed: 8/20: Lp(a) has gained attention due to its association with adverse outcomes. For example, an Lp(a) >190 nmol/L has been…
0
4
0
RT @n_marreromed: 7/20: Sex differences in Lp(a) concentration exist with 17% ⬆️ concentrations in women > age 50. Despite ethnic and sex-b…
0
4
0
RT @n_marreromed: 6/20: Racial/ethnic differences in Lp(a) levels exist: The lowest concentrations have been reported among those from East…
0
4
0
RT @n_marreromed: 5/20: Lp(a) concentration is > 90% determined by genetic variability at the LPA locus with ~20% of the population having…
0
4
0
RT @n_marreromed: 4/20: When interpreting Lp(a) levels, it is important to understand that levels are reported using different lab assays:…
0
3
0
RT @n_marreromed: 2/20: Our Learning Objectives: 🔺Describe the structure and pathophysiology of Lp(a) 🔺Understand the epidemiology of Lp(a)…
0
4
0
RT @n_marreromed: 1/20: 50 y/o M with HTN & a family history of premature CAD presents to discuss the results of his labs. His Lp(a) is 200…
0
14
0
RT @IM_Crit_: ICU Stories: 70 yo pt w history of A. fib presented to the ED 4 d earlier w slurred speech/diplopia/weakness. CT brain: no s…
0
123
0